Grünenthal receives FDA Breakthrough Therapy Designation for knee osteoarthritis drug
May 23, 2023Medical Communications Breakthrough Therapy Designation, FDA, Grunenthal, Musculo-skeletal disorder, osteoarthritis
German pharmaceutical company Grünenthal has announced that the US Food and Drug Administration (FDA) has awarded it Breakthrough Therapy Designation …
FDA approves prescription nasal spray for opioid overdose treatment
May 23, 2023Medical Communications FDA, Nasal Spray, Opvee, Poisoning and drug dependency, opioids, overdose
The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the first nalmefene hydrochloride nasal spray …
Oncimmune Holdings sells businesses to Freenome in £13m deal
May 22, 2023Sales and Marketing Freenome, Oncimmune Holdings, Oncology, acquisition
UK-based life sciences and immunodiagnostics firm Oncimmune Holdings has announced that it has sold its Oncimmune Limited and Oncimmune Europe …
FDA approves new insulin pump and algorithm software for enhanced automated insulin delivery
May 22, 2023Medical Communications Devices, FDA, diabetes, insulin
The US Food and Drug Administration (FDA) has announced that it has cleared the Beta Bionics iLet ACE Pump and …
Swing Therapeutics receives FDA authorisation for digital therapeutic for fibromyalgia
May 22, 2023Medical Communications CBT, Devices, FDA, Swing Therapeutics, fibromyalgia
Swing Therapeutics has announced that it has received De Novo marketing authorisation from the US Food and Drug Administration for …
Krystal Biotech secures FDA approval for redosable topical gene therapy
May 22, 2023Medical Communications FDA, Krystal Biotech, Paediatrics, dystrophic epidermolysis bullosa, gene therapy
US-based biotech company Krystal Biotech has announced that the US Food and Drug Administration (FDA) has approved its topical gene …
FDA committee votes in favour of Pfizer’s RSV vaccine for maternal immunisation
May 19, 2023Research and Development FDA, Immunology, Pfizer, RSV, Vaccine, maternal immunisation
Pfizer has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) from the US Food and Drug Administration …
FDA approves Abbott’s Assert-IQ insertable cardiac monitor
May 19, 2023Research and Development Abbott, Cardiology, Devices, FDA, heart monitor, medical devices
Abbott has announced that the US Food and Drug Administration (FDA) has granted its clearance for the Assert-IQ insertable cardiac …
Schott Pharma announces pre-filled polymer syringes for deep-cold medication
May 19, 2023Medical Communications Devices, Schott Pharma, deep cold medication, syringe
Germany-based drug delivery solutions company Schott Pharma has announced its pre-fillable syringes (PFS) for drugs requiring deep-cold, such as those …
NHS given guidance on offering genetic testing to stroke patients
May 19, 2023Medical Communications NHS, Neurology, blood clot, genetic testing, stroke
The NHS has been given draft guidance on offering gene tests to patients who have had a stroke caused by …
Is the pharmaceutical sector prepared to face a titanium dioxide ban?
May 19, 2023Manufacturing and Production ACG, EMA, EU, Titanium Dioxide
Dr Subhashis Chakraborty, head of Global Product Management, ACG Capsules In the wake of the ban on titanium dioxide (TiO2) …
NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus
May 18, 2023Medical Communications Kapruvia, NICE, Nephrology, chronic kidney disease, pruritus
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National Institute for Health and Care …
US appeals court hears arguments in abortion pill case
May 18, 2023Medical Communications Obstetrics & Gynaecology, abortion, medication abortion, mifepristone, reproduction
The ongoing court battle surrounding the contested approval of mifepristone, one of the drugs used in medication abortions, has now …
Servier and Aitia enter into R&D collaboration for pancreatic cancer using Digital Twins
May 18, 2023Research and Development Aitia, Digital Twins, Oncology, Pancreatic cancer, Servier
French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced a collaboration to create Digital …
Asieris Pharmaceuticals and Uroviu announce strategic collaboration to further develop integrated diagnosis and treatment for bladder cancer
May 18, 2023Research and Development Asieris Pharmaceuticals, Diagnostics, Oncology, Uroviu, bladder cancer, oncology
US-based biopharmaceutical company Asieris Pharmaceuticals and single-use endoscopic platform creator Uroviu have announced that they have entered into a strategic …
Nemours Children’s Health selected to conduct first gene therapy for Morquio A syndrome
May 17, 2023Research and Development Morquio A syndrome, NIH, Nemours Children's Health, Paediatrics, gene therapy
Nemours Children’s Health, based in Delaware, US, has been chosen by the Foundation for the National Institutes of Health (FNIH) …
AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy
May 17, 2023Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy
AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …
NICE recommends nine digital treatment options for depression and anxiety
May 17, 2023Medical Communications NICE, Neurology, anxiety, depression, digital health, mental health
The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety …
FDA grants Priority Review for Takeda’s cTTP treatment
May 17, 2023Research and Development Biologics License Application, Cardiology, FDA, Takeda, cTTP
Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application …
RadioMedix and Orano Med complete patient enrolment for neuroendocrine cancer trial
May 16, 2023Medical Communications Oncology, Orano Med, RadioMedix, neuroendocrine cancer, oncology
US-based RadioMedix and French Orano Med, two clinical stage radiopharmaceutical companies, have announced that the last patient has been enrolled …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
